Poland· PL-100493019
Krazati
A adagrasib product containing adagrasibum, registered in Poland by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 9 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Adagrasib is registered in 9 of 19 countries.
Countries holding a registration under ATC L01XX77 (adagrasib), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 6 of them publish a price we can compare per daily dose
Adagrasib · ATC L01XX77
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Adagrasibum
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG
- Country
- Poland (PL)
- ATC code
- L01XX77
- ATC class
- Adagrasib
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin08027950801718
- gtin03400930295175
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Adagrasib in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaKRAZATIBristol-Myers Squibb Pharma EEIG, Dublin
- FinlandKRAZATIBristol-Myers Squibb Pharma EEIG
- BelgiumKrazati 200 mgBristol-Myers Squibb Pharma
- IcelandKrazatiBristol-Myers Squibb Pharma EEIG
- NetherlandsKrazati 200 mg, filmomhulde tabletBristol-Myers Squibb Pharma EEIG
- SwedenKRAZATI 200 mg Filmdragerad tablettBristol-Myers Squibb Pharma EEIG
- IrelandKRAZATI 200 mg film-coated tabletsBristol-Myers Squibb Pharma EEIG
- United StatesKRAZATIMirati Therapeutics, Inc
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Krazati
- Liechtenstein · Krazati
- Norway · Krazati
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3f9a62ac-36ad-498b-a579-0d1711f3e580 GET /v1/drugs/3f9a62ac-36ad-498b-a579-0d1711f3e580?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "200 mg",
"packaging": "Rpz ¦ EU/1/23/1744/001 ¦ 153076\n120 tabl.\n08027950801718 ¦ Rpz ¦ EU/1/23/1744/002 ¦ 153077\n180 tabl.\n¦ UR/Z/4c/032/25 - 03400930295175",
"substance": "Adagrasibum 200 mg",
"common_name": "Adagrasibum",
"pl_product_id": "100493019",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about adagrasib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.